Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
183.38
+2.71 (1.50%)
At close: Apr 28, 2026, 4:00 PM EDT
181.59
-1.79 (-0.97%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Biogen Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for Biogen stock have an average target of 203.16, with a low estimate of 115 and a high estimate of 275. The average target predicts an increase of 10.79% from the current stock price of 183.38.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Biogen stock from 26 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 8 | 8 | 8 |
| Buy | 4 | 4 | 5 | 4 | 4 | 6 |
| Hold | 14 | 12 | 14 | 15 | 15 | 11 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 25 | 28 | 28 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold → Strong Buy Upgrades $185 → $225 | Hold → Strong Buy | Upgrades | $185 → $225 | +22.70% | Apr 22, 2026 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $200 → $250 | Hold → Buy | Upgrades | $200 → $250 | +36.33% | Apr 20, 2026 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $177 → $214 | Hold → Buy | Upgrades | $177 → $214 | +16.70% | Apr 14, 2026 |
| Citigroup | Citigroup | Hold Maintains $215 → $190 | Hold | Maintains | $215 → $190 | +3.61% | Apr 13, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $193 → $189 | Hold | Maintains | $193 → $189 | +3.06% | Apr 13, 2026 |
Financial Forecast
Revenue This Year
9.67B
from 9.89B
Decreased by -2.26%
Revenue Next Year
9.63B
from 9.67B
Decreased by -0.35%
EPS This Year
16.12
from 8.79
Increased by 83.42%
EPS Next Year
16.35
from 16.12
Increased by 1.40%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.4B | 11.0B | ||||||
| Avg | 9.7B | 9.6B | ||||||
| Low | 9.1B | 8.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.5% | 14.2% | ||||||
| Avg | -2.3% | -0.4% | ||||||
| Low | -8.1% | -11.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 17.14 | 19.08 | ||||||
| Avg | 16.12 | 16.35 | ||||||
| Low | 14.05 | 13.51 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 94.9% | 18.4% | ||||||
| Avg | 83.4% | 1.4% | ||||||
| Low | 59.9% | -16.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.